MARSEILLE, France–(Business Wire)–Supervision News:
Innate Pharma SA (OTC: ) (Euronext Paris: IPH; Nasdaq: IPHA) (innate or company) announced today that members of its executive team plan to attend the upcoming meeting, details below. Participants include Yannis Morel, executive vice president and chief operating officer, and Arvind Sood, executive vice president and president of U.S. operations.
- BTIG Virtual Biotechnology Conference
date: August 5-6, 2024 | Virtual
About Xiantian Pharmaceutical
Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapies for patients with cancer. Its innovative approach aims to deliver therapeutic antibodies and its ANKET® (AAntibody-based NK cells cell SecondRoar timetherapeutics) proprietary platform.
Innate’s product portfolio includes lead proprietary programs lacutamab in development for cutaneous T-cell lymphoma and advanced forms of peripheral T-cell lymphoma, monalizumab for non-small cell lung cancer in partnership with AstraZeneca (NASDAQ: ) , and ANKET ® multispecific NK cell engager to address multiple tumor types.
Innate Pharma is a trusted partner for biopharmaceutical companies such as Sanofi (Nasdaq: ) and AstraZeneca, as well as leading research institutions, accelerate innovation, research and development to benefit patients.
Innate Pharma is headquartered in Marseille, France, with U.S. offices in Rockville, Maryland, and is listed on Euronext Paris and NASDAQ in the United States.
To learn more about Innate Pharma, visit www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma stock
|
ISIN code |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer Regarding Forward-Looking Information and Risk Factors
This press release contains certain forward-looking statements, including statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, including related to safety, the progress and results of ongoing and planned clinical trials and preclinical studies, regulatory review and approval of its product candidates , the Company’s commercialization efforts and the Company’s ability to continue to raise capital to fund its growth. For a further discussion of the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in forward-looking statements, please see the General Company’s Risk Factors (Facteurs de Risque) section. To France Registration documents filed with the Authority for the Financial Markets (AMF) (available on the AMF website at http://www.amf-france.org or on the Innate Pharma website) and public documents and reports filed with the U.S. Securities and Exchange Commission ( SEC), including the Company’s annual report on Form 20-F for the year ended December 31, 2023, and subsequent documents and reports filed by the Company with the AMF or SEC or otherwise made public.
This press release and the information contained therein does not constitute an offer to sell Innate Pharma shares in any country, nor does it constitute a solicitation of an offer to buy or subscribe for Innate Pharma shares.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731971255/en/
For more information please contact:
investor
Xiantian Pharmaceutical
Henry Wheeler
Tel: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
media relations
new capital
Arthur Ruyer
Tel: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma
